UCSF

The exquisite specificity and affinity for their target antigens makes radiolabeled antibodies attractive candidates for therapeutics and drug delivery agents. The aim of this study was to evaluate the potential utility of two clinically available antibodies, Certolizumab Pegol (Cimzia) and Pembrolizumab (Pembro) for immuno-PET imaging. Methods: Antibodies pembrolizumab and certolizuman pegol were labeled with 89Zr in high chemical and radiochemical purity. Results: 89Zr-DFO-Pembro and 89Zr-DFO-Cimzia have been prepared with high radiochemical purity (>95%) with good radiochemical yield (~70%). Conclusion: Results from this studies will provide requisite data for an IND submission to the FDA and ultimately clinical translation of 89Zr-DFO-Pembro and 89Zr-DFO-Cimzia.